A Phase Ib/III Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Immunogenicity of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
Latest Information Update: 22 May 2024
At a glance
- Drugs Aumolertinib (Primary) ; PM 1080 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Hansoh BioMedical R&D Company
Most Recent Events
- 21 May 2024 New trial record